// App-Quantinova.ai

: Treatable traits in the NOVELTY study: prevalence, patterns and relationship with physician-assessed severity

Researchers

Presenter

  • Alvar Agusti

Principal Investigators

  • Eleni Rapsomaniki

  • Richard Beasley

  • Rod Hughes

  • Hana Müllerová

  • Alberto Papi

  • Ian D Pavord

  • Rosa Faner

Medical Centers

  • Respiratory Institute, Hospital Clinic, University of Barcelona, IDIBAPS, CIBER, Barcelona, Spain,

  • GMA Diabetes, BioPharmaceuticals Med, AstraZeneca, Cambridge, United Kingdom

  • Respiratory Medicine Unit, Dept of Medical Sciences, Università di Ferrara, Ferrara, Italy

  • Respiratory Medicine Unit and Oxford Respiratory NIHR BRC, Nuffield Department of Medicine, University of Oxford, Oxford, United Kingdom

  • IDIBAPS, Centro de Investigación Biomedica en Red M.P, Barcelona, Spain

  • Medical Research Institute of New Zealand (MRINZ), Wellington, New Zealand

Locations

  • Italy

  • Spain

  • United Kingdom

  • New Zealand

Companies

  • N/A

Study Components

Therapeutic Area

  • Pulmonary/Respiratory Diseases

  • Autoimmune (AI)

Disease

  • Asthma

  • Chronic obstructive pulmonary disease

Biomarkers

  • N/A

Drug/Treatment

  • N/A

Outcome

  • N/A

Study Design

  • N/A

Phase

  • N/A

Study Id's

  • NCT02760329

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved